

P. Roberts*; F. Miyajima; A. Swale; K. Antoniou; M. Little; G. Smith; N. Beeching; C. Parry; M. Pirmohamed

NIHR - Liverpool Biomedical Research Centre, Liverpool, L69 3GA (*Contact: paulmm@liv.ac.uk)

BACKGROUND

- The incidence and severity of *Clostridium difficile* infection (CDI) has considerably increased in the last decade.
- This has coincided with the emergence of epidemic strains, particularly PCR-ribotype 027 that has caused hospital outbreaks in North America and Europe.
- PCR-ribotype 027 has recently become the predominant strain in the United Kingdom. There is growing evidence that this strain also accounts for higher morbidity and mortality.
- Several authors have warned that *C. difficile* isolates are becoming increasingly more resistant to metronidazole and vancomycin, mainstay antimicrobials used for CDI therapy.


OBJECTIVES

- To investigate the prevalence of PCR-ribotype 027 (NAP1/BI/gc-8) among patients consecutively recruited into a prospective study and then compare with the historical strain distribution observed in the previous decades in our hospital.
- To assess its association with several clinical parameters used to evaluate the course of the disease.
- To determine the MIC of metronidazole and vancomycin for a collection of isolates based on their temporal distribution in our hospital.

METHODS

- Faecal samples were tested for *C. difficile* toxin using a TOX A/B II ELISA kit (Techlab, Blacksburg, USA) and patients with toxin-positive results were approached to participate in a prospective study on CDI.
- Ethical approval was obtained from the Liverpool Research Ethics Committee and patient information was extracted using the hospital's medical records system.
- One hundred seventy seven (177) CDI inpatients were recruited and followed-up in a large hospital setting in Liverpool between July 2008 and June 2010.
- Toxin positive samples were screened for faecal leukocytes (an indicator of intestinal inflammation) by microscopy of a wet preparation of faecal sample.
- Faecal samples were cultured for the isolation of strains and to confirm toxigenicity and determine ribotype groups.
- The MIC of metronidazole and vancomycin was determined by the E-test method.
- Clinical outcomes included determination of peak of disease severity (based on the HPA guidelines) over the 30-day follow-up period.

STUDY DESIGN



INITIAL RESULTS

- *Clostridium difficile* PCR-ribotype 027 was the most commonest strain isolated from our cohort (45%), followed by types 106 (18%) and 078 (8%). Surveillance assessment also confirmed that type 027 was the main circulating strain in our hospital.
- Comparative analysis of current strains with a collection of historical strains suggests a shift towards PCR-ribotype 027 and a decrease in the diversity of strains (Figure 1).
- The distribution of PCR-ribotype 027 was significantly greater among individuals who had tested positive for the presence of faecal leukocytes (54% vs. 35%, $p=0.04$) (Figure 2 and Table 1).
- PCR-ribotype 027 also predicted higher levels of toxins A/B as measured by OD values ($\alpha=0.94$, $p=0.014$) (Table 1).
- Symptomatic patients carrying this strain were significantly more likely to present severe disease within the follow-up period (OR=2.57, $p=0.005$) (Table 1).
- We found no evidence of resistance to vancomycin and metronidazole in our *C. difficile* isolates (Figures 3 and 4).




Figure 1 – Distribution of common ribotypes in the Royal Liverpool University Hospital.




Figure 2 – Current distribution of *Clostridium difficile* PCR-ribotypes based on the presence or absence of faecal leukocytes

Table 1 – Results of the univariate analysis

Association results with PCR-ribotype 027		
Parameters	P-value	Values (C.I. 95%)
Presence of Faecal Leukocytes vs. Absence	0.019	OR=2.15 (1.13, 4.09)
Level of toxins A/B (OD quantile regression)	0.014	C=+0.94 (0.19, 1.69)
Peak of severe disease (4-week follow-up)	0.005	OR=2.57 (1.32, 5.01)
Total number of observations: n=153		




Figure 3 – Minimum Inhibitory Concentration distribution for Metronidazole (n=61)




Figure 4 – Minimum Inhibitory Concentration distribution for Vancomycin (n=61)

CONCLUSIONS

- Our results suggest that there are important clinical features associated with symptomatic colonisation with PCR-ribotype 027, such as severity of the disease and higher levels of intestinal inflammation as denoted by the presence of faecal leukocytes.
- Although our results are interesting, further investigation is needed to validate our findings. This will be performed by using a replication set of samples.
- Additional work includes the determination of MIC per PCR-ribotype group for the entire collection of isolates.
- Further molecular screening using more discriminatory typing techniques would aid in the detection of sub-types of PCR-ribotypes allowing to track dynamic changes in the pathogen.